3-(3-Amino-propoxy)-benzoic acid methyl ester | 892492-49-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(3-Amino-propoxy)-benzoic acid methyl ester
• 英文别名: Methyl 3-(3-aminopropoxy)benzoate
• CAS: 892492-49-8
• 化学式: C₁₁H₁₅NO₃
• mdl: MFCD24390396
• 分子量: 209.245
• InChiKey: IHZXWGSXWMRLMR-UHFFFAOYSA-N

物化性质

• 沸点：
  336.8±22.0 °C(Predicted)
• 密度：
  1.112±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  61.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(3-Amino-propoxy)-benzoic acid methyl ester 在 sodium hydroxide 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 21.0h， 生成 3-[3-(3-Chloro-benzenesulfonylamino)-propoxy]-benzoic acid
  参考文献：
  名称：

  Synthesis and activities of new arylsulfonamido thromboxane A2 receptor antagonists

  摘要：

  New benzoic, benzeneacetic and thiazole-4-acetic acids bearing an arylsulfonamido alkyl or alkylhetero side chain were synthesized and tested in vitro for affinity for human platelet thromboxane A2 receptors and inhibition of U46619-induced rat aortic ring contraction. Influence of substitution patterns, chain length and presence of heteroatoms were studied and compounds within a 30 nmol range for inhibition of U46619-induced contractions were found. One of the most potent, 2-[(4-chloro-benzenesulfonylamino-ethyl)thio] thiazole-4-acetic acid (VII-4) was orally active (1 mg/kg), as evidenced by the inhibition of U46619-induced platelet aggregation in guinea pigs, ex vivo.

  DOI：

  10.1016/0223-5234(93)90093-t
• 作为产物：
  描述：

  3-[3-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-propoxy]-benzoic acid methyl ester 在 一水合肼 作用下， 以 甲醇 为溶剂， 反应 8.0h， 生成 3-(3-Amino-propoxy)-benzoic acid methyl ester
  参考文献：
  名称：

  Synthesis and activities of new arylsulfonamido thromboxane A2 receptor antagonists

  摘要：

  New benzoic, benzeneacetic and thiazole-4-acetic acids bearing an arylsulfonamido alkyl or alkylhetero side chain were synthesized and tested in vitro for affinity for human platelet thromboxane A2 receptors and inhibition of U46619-induced rat aortic ring contraction. Influence of substitution patterns, chain length and presence of heteroatoms were studied and compounds within a 30 nmol range for inhibition of U46619-induced contractions were found. One of the most potent, 2-[(4-chloro-benzenesulfonylamino-ethyl)thio] thiazole-4-acetic acid (VII-4) was orally active (1 mg/kg), as evidenced by the inhibition of U46619-induced platelet aggregation in guinea pigs, ex vivo.

  DOI：

  10.1016/0223-5234(93)90093-t

文献信息

• Oxadiazole Derivative as Dgat Inhibitors
  申请人：Birch Martin Alan

  公开号：US20080096874A1

  公开（公告）日：2008-04-24

  Compounds of formula (I), and salts and pro-drugs thereof: Formula (I) wherein for example R 1 is optionally substituted aryl or heteroaryl; Y is a linking group selected from, for example, a direct bond, and a (substituted) alkyl chain; R 2 is an optionally substituted aryl, an optionally substituted cycloalkyl or an optionally substituted heterocyclic group; are described. Processes to make such compounds and their use as DGAT inhibitors, for example in the treatment of obesity, are also described.

  式（I）的化合物，以及其盐和前药：其中，例如R1是可选取代芳基或杂环芳基；Y是选择自直接键和（取代）烷基链等的连接基；R2是可选取代芳基、可选取代环烷基或可选取代杂环基团。还描述了制备此类化合物的方法及其作为DGAT抑制剂的用途，例如在肥胖症的治疗中。
• Oxadiazole derivative as DGAT inhibitors
  申请人：AstraZeneca AB

  公开号：US07795283B2

  公开（公告）日：2010-09-14

  Compounds of formula (I), and salts and pro-drugs thereof: Formula (I) wherein for example R1 is optionally substituted aryl or heteroaryl; Y is a linking group selected from, for example, a direct bond, and a (substituted) alkyl chain; R2 is an optionally substituted aryl, an optionally substituted cycloalkyl or an optionally substituted heterocyclic group; are described. Processes to make such compounds and their use as DGAT inhibitors, for example in the treatment of obesity, are also described.

  公式（I）的化合物，以及其盐和前药： 公式（I）其中例如R1是可选取代芳基或杂环芳基; Y是选自直接键和（取代）烷基链等连接基团; R2是可选取代芳基，可选取代环烷基或可选取代杂环基团的化合物已被描述。还描述了制备这些化合物的过程以及它们作为DGAT抑制剂的用途，例如在肥胖症的治疗中。
• OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS
  申请人：BIRCH Alan Martin

  公开号：US20100317653A1

  公开（公告）日：2010-12-16

  Compounds of formula (I), and salts and pro-drugs thereof: wherein for example R 1 is optionally substituted aryl or heteroaryl; Y is a linking group selected from, for example, a direct bond, and a (substituted) alkyl chain; R 2 is an optionally substituted aryl, an optionally substituted cycloalkyl or an optionally substituted heterocyclic group; are described. Processes to make such compounds and their use as DGAT inhibitors, for example in the treatment of obesity, are also described.

  公式（I）的化合物、其盐和前药：其中，例如，R1是可选取代芳基或杂环芳基；Y是选自直接键和（取代）烷基链的连接基；R2是可选取代芳基、可选取代环烷基或可选取代杂环基团。本文描述了制备这种化合物的过程，以及它们作为DGAT抑制剂的用途，例如用于治疗肥胖症。
• US7795283B2
  申请人：——

  公开号：US7795283B2

  公开（公告）日：2010-09-14
• [EN] OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS<br/>[FR] DÉRIVÉS D'OXADIAZOLE EN TANT QU'INHIBITEURS DE DGAT
  申请人：ASTRAZENECA AB

  公开号：WO2006064189A1

  公开（公告）日：2006-06-22

  [EN] Compounds of formula (I), and salts and pro-drugs thereof: Formula (I) wherein for example R¹ is optionally substituted aryl or heteroaryl; Y is a linking group selected from, for example, a direct bond, and a (substituted) alkyl chain; R² is an optionally substituted aryl, an optionally substituted cycloalkyl or an optionally substituted heterocyclic group; are described. Processes to make such compounds and their use as DGAT inhibitors, for example in the treatment of obesity, are also described.
  [FR] La présente invention décrit des composés de formule (I), ainsi que des sels et des prodrogues desdits composés : Formule (I) selon laquelle, par exemple, R¹ est un groupement aryle ou hétéroaryle éventuellement substitué ; Y est un groupement de liaison sélectionné parmi, par exemple, une liaison directe et une chaîne alkyle éventuellement substituée ; R² est un groupement aryle éventuellement substitué, ou un groupement cycloalkyle éventuellement substitué, ou un groupement hétérocyclique éventuellement substitué. La présente invention décrit également des procédés de synthèse de tels composés, ainsi que leur utilisation en tant qu'inhibiteurs de DGAT, par exemple dans le traitement de l'obésité.